NCT07610798 2026-05-28A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D MutationsShenzhen Ionova Life Sciences Co., Ltd.Phase 1/2 Not yet recruiting178 enrolled